Drug Profile
DLBS 1449
Alternative Names: DLBS1449; ForhidrolLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Dexa Medica
- Class Antihyperlipidaemics; Phytotherapies
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Dyslipidaemias in Indonesia (PO, Capsule)
- 03 Aug 2016 Dexa Medica withdraws a phase II/III trial for Dyslipidaemias in Indonesia prior to enrolment (NCT01972477)
- 16 Dec 2013 Dexa Medica plans a phase II/III trial for Dyslipidaemias in Indonesia (NCT01972477)